Author name: Leonardo Arias

Johnson & Johnson will discontinue the Phase II Auτonomy study of posdinemab after a scheduled review found the anti-tau antibody failed to slow clinical decline in patients with early Alzheimer’s disease.

Analysts agree that the failure of Novo Nordisk’s semaglutide to reduce Alzheimer’s disease progression removes a “modest” or “perceived” overhang on Biogen and the anti-amyloid antibody class in general, clearing the way for increased uptake of Leqembi and Eli Lilly’s Kisunla.

Funding through the third quarter surpassed last year’s total, according to PitchBook. Meanwhile, average deal sizes are skyrocketing as high valuations — especially for AI startups — drive larger rounds.

The medtech firm plans to launch its next flagship patch-pump in 2027, and its first fully closed loop system for Type 2 diabetes in 2028.

“We felt we had a responsibility to explore semaglutide’s potential, despite a low likelihood of success,” Martin Holst Lange, Novo’s R&D chief, said on Monday.

Post Content

Asundexian’s Phase III win could also bode well for Bristol Myers Squibb, which is also developing a Factor XIa inhibitor called milvexian for stroke prevention, analysts said.

NervGen will meet with the FDA early next year to align on a regulatory path forward for NVG-291 in chronic spinal cord injury.

Subirse a la parte superior de las turbinas eólicas para inspeccionarla puede resultar muy aparatoso para los operarios humanos. Debido a ello, la idea de usar drones de manera habitual para inspecciones de rutina es una opción que ha cobrado fuerza.   Un ejemplo reciente de est …

Noticias de la actualidad astronómica y astronáutica del 24 de noviembre de 2025.     …